Literature DB >> 17027073

Intraperitoneal chemotherapy and the NCI clinical announcement.

Edward L Trimble1, Ronald D Alvarez.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 17027073     DOI: 10.1016/j.ygyno.2006.08.020

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  9 in total

Review 1.  Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.

Authors:  Ramez N Eskander; James Cripe; Robert E Bristow
Journal:  Curr Treat Options Oncol       Date:  2014-03

2.  Practical considerations in ovarian cancer chemotherapy.

Authors:  Mihaela Cristea; Ernest Han; Lennie Salmon; Robert J Morgan
Journal:  Ther Adv Med Oncol       Date:  2010-05       Impact factor: 8.168

3.  The Basic Study of Liposome in Temperature-Sensitive Gel at Body Temperature for Treatment of Peritoneal Dissemination.

Authors:  Ikumi Sugiyama; Kaana Ando; Yasuyuki Sadzuka
Journal:  Gels       Date:  2022-04-20

4.  Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study.

Authors:  Peng-Cheng Li; Liang-Dong Chen; Fang Zheng; Yan Li
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-31       Impact factor: 4.553

5.  Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.

Authors:  Harriet O Smith; James Moon; Sharon P Wilczynski; Amy D Tiersten; Edward V Hannigan; William R Robinson; Saul E Rivkin; Garnet L Anderson; P Y Liu; Maurie Markman
Journal:  Gynecol Oncol       Date:  2009-05-23       Impact factor: 5.482

Review 6.  Major clinical research advances in gynecologic cancer in 2013.

Authors:  Dong Hoon Suh; Jae-Weon Kim; Sokbom Kang; Hak Jae Kim; Kyung-Hun Lee
Journal:  J Gynecol Oncol       Date:  2014-07-03       Impact factor: 4.401

Review 7.  Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1).

Authors:  Muhammad Wasif Saif; Andrew Heaton; Kimberley Lilischkis; James Garner; David M Brown
Journal:  Cancer Chemother Pharmacol       Date:  2016-12-24       Impact factor: 3.333

8.  Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.

Authors:  Kenzo Iizuka; Cheng Jin; Kokoro Eshima; Mei Hua Hong; Kiyoshi Eshima; Masakazu Fukushima
Journal:  Drug Des Devel Ther       Date:  2018-03-29       Impact factor: 4.162

9.  Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.

Authors:  Kyung Jin Eoh; Jung Yun Lee; Eun Ji Nam; Sunghoon Kim; Young Tae Kim; Sang Wun Kim
Journal:  J Korean Med Sci       Date:  2017-12       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.